1. [CCR5 antagonists: a new class of antiretrovirals]
- Author
-
X, de la Tribonnière, Y, Yazdanpanah, and J, Reynes
- Subjects
Maraviroc ,Clinical Trials as Topic ,Pyrimidines ,Cyclohexanes ,HIV Fusion Inhibitors ,CCR5 Receptor Antagonists ,Humans ,HIV Infections ,Spiro Compounds ,Diketopiperazines ,Triazoles ,Benzoates ,Piperazines - Abstract
Inhibition of CCR5 co-receptor which is also a chemokine receptor, is a new way for inhibition of HIV-1 replication. Small antagonist molecules exert non competitive inhibition of the HIV co-receptor CCR5, which is essential for HIV entry. The CCR5 antagonists aplaviroc (GlaxoSmithKine), vicriviroc (Schering-Plough), and maraviroc (Pfizer) have reached phases III of clinical development. The development of aplaviroc was stopped because of its hepatotoxicity in some of the HIV-infected patients. In ACTG 5211 and MOTIVATE trials, treatment-experienced subjects who added respectively vicriviroc and maraviroc demonstrated substantially greater reductions in plasma HIV-1 RNA levels than those who received the placebo ; maraviroc currently having obtained European authorization. The place of this new class in the strategies of initial, switch or rescue treatment remains to be clarified. The limitations of the use of these small molecules depend on their mechanism of action : obligation for monitoring the evolution of coreceptor usage, risk of failure by emergence of pre-existing strains with CXCR4 (X4) tropism or by resistant strains with CCR5 tropism, potential risks related to blocking of the physiological functions of this chemokine receptor.
- Published
- 2008